Rotigotine
Rotigotine is a non-ergoline dopamine receptor agonist delivered transdermally, used primarily for the treatment of Parkinson's disease and restless legs syndrome, with investigational applications in Alzheimer's disease and epilepsy. It acts as an agonist at D1, D2, and D3 dopamine receptors, as well as alpha-adrenergic and serotonin receptors, restoring dopaminergic tone in the striatum. Continuous transdermal delivery provides stable plasma levels, reducing motor fluctuations.
Молекулярная масса
315,5000 g/mol
LogP
4,90
TPSA
51,70 Ų
Правило пяти Липинского
Соответствует
Терапевтические области
Механизм действия
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
2D Структура
Cite this structure
Embed this structure
SMILES
CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1
InChI
InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
Molecular Formula
C19H25NOS
HBD / HBA
1 / 3
Вращаемые Связи
6
Тяжёлые Атомы
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
Rotigotine is a non-ergoline dopamine receptor agonist delivered transdermally, used primarily for the treatment of Parkinson's disease and restless legs syndrome, with investigational applications in Alzheimer's disease and epilepsy. It acts as an agonist at D1, D2, and D3 dopamine receptors, as well as alpha-adrenergic and serotonin receptors, restoring dopaminergic tone in the striatum. Continuous transdermal delivery provides stable plasma levels, reducing motor fluctuations.
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Rotigotine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1303. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 59227. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rotigotine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rotigotine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rotigotine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rotigotine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rotigotine"></drugfyi-drug>